Shares of Sage Therapeutics jumped on Monday after it announced positive results in a midstage study of a drug for the treatment of major depressive disorder.
The stock was 14 percent higher in midday trading. It ended the day slightly below that level, but still gained nearly 12 percent during the session.
In a release on Monday, the Massachusetts-based company said it found encouraging results in a placebo-controlled phase 2 clinical trial for its orally-administered SAGE-217.
